Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials

BACKGROUND: Although the addition of bevacizumab to 1(st )line chemotherapy provides a significant survival benefit for advanced colorectal cancer, the magnitudes of both advantages and toxicities have not been extensively investigated. METHODS: A literature-based meta-analysis was conducted; Hazard...

Descripción completa

Detalles Bibliográficos
Autores principales: Loupakis, Fotios, Bria, Emilio, Vaccaro, Vanja, Cuppone, Federica, Milella, Michele, Carlini, Paolo, Cremolini, Chiara, Salvatore, Lisa, Falcone, Alfredo, Muti, Paola, Sperduti, Isabella, Giannarelli, Diana, Cognetti, Francesco
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890550/
https://www.ncbi.nlm.nih.gov/pubmed/20504361
http://dx.doi.org/10.1186/1756-9966-29-58

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890550/
https://www.ncbi.nlm.nih.gov/pubmed/20504361
http://dx.doi.org/10.1186/1756-9966-29-58

Ejemplares similares